These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15151522)

  • 1. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Br J Clin Pharmacol; 2004 Jun; 57(6):764-72. PubMed ID: 15151522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the validity of a population pharmacokinetic model for epirubicin.
    Ralph LD; Sandstrom M; Twelves C; Dobbs NA; Thomson AH
    Br J Clin Pharmacol; 2006 Jul; 62(1):47-55. PubMed ID: 16842378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
    Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
    Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New sampling strategy using a Bayesian approach to assess iohexol clearance in kidney transplant recipients.
    Benz-de Bretagne I; Le Guellec C; Halimi JM; Gatault P; Barbet C; Alnajjar A; Büchler M; Lebranchu Y; Andres CR; Vourcʼh P; Blasco H
    Ther Drug Monit; 2012 Jun; 34(3):289-97. PubMed ID: 22585184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
    Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres.
    Sottani C; Poggi G; Quaretti P; Regazzi M; Montagna B; Quaquarini E; Imbriani M; Leoni E; Di Cesare P; Riccardi A; Bernardo G; Minoia C
    Anticancer Res; 2012 May; 32(5):1769-74. PubMed ID: 22593459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
    Bos AM; Boom K; Vinks AA; Boezen HM; Wanders J; Dombernovsky P; Aamdal S; de Vries EG; Uges DR
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Iliadis A
    Cancer Chemother Pharmacol; 1995; 36(3):233-8. PubMed ID: 7781144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sampling strategies to assess inulin clearance in children by the inulin single-injection method.
    van Rossum LK; Mathot RA; Cransberg K; Vulto AG
    Clin Chem; 2003 Jul; 49(7):1170-9. PubMed ID: 12816915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
    van Kesteren C; Mathĵt RA; López-Lázaro L; Cvitkovic E; Taamma A; Jimeno JM; Guzman C; Schellens JH; Misset JL; Brain E; Hillebrand MJ; Rosing H; Beijnen JH
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):459-66. PubMed ID: 11800026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics.
    Amsden GW; Ballow CH
    Pharmacotherapy; 1996; 16(5):937-41. PubMed ID: 8888090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941.
    Jodrell DI; Murray LS; Hawtof J; Graham MA; Egorin MJ
    Cancer Chemother Pharmacol; 1996; 37(4):356-62. PubMed ID: 8548882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.